Abbott Laboratories $ABT Stake Lifted by Fulcrum Capital LLC

Fulcrum Capital LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,638 shares of the healthcare product maker’s stock after buying an additional 890 shares during the period. Abbott Laboratories comprises approximately 1.3% of Fulcrum Capital LLC’s investment portfolio, making the stock its 29th biggest position. Fulcrum Capital LLC’s holdings in Abbott Laboratories were worth $6,343,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ABT. Hughes Financial Services LLC bought a new stake in Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories in the 1st quarter worth approximately $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories in the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter worth approximately $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth approximately $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 0.8%

NYSE:ABT opened at $132.30 on Friday. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market cap of $230.26 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.53 and a beta of 0.69. The stock has a 50-day moving average price of $132.54 and a two-hundred day moving average price of $131.56.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Mizuho raised their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Evercore ISI raised their price target on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Royal Bank Of Canada raised their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $146.17.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.